Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses

Masaru Kanekiyo, M Gordon Joyce, Rebecca A Gillespie, John R Gallagher, Sarah F Andrews, Hadi M Yassine, Adam K Wheatley, Brian E Fisher, David R Ambrozak, Adrian Creanga, Kwanyee Leung, Eun Sung Yang, Seyhan Boyoglu-Barnum, Ivelin S Georgiev, Yaroslav Tsybovsky, Madhu S Prabhakaran, Hanne Andersen, Wing-Pui Kong, Ulrich Baxa, Kathryn L Zephir, Julie E Ledgerwood, Richard A Koup, Peter D Kwong, Audray K Harris, Adrian B McDermott, John R Mascola, Barney S Graham, Masaru Kanekiyo, M Gordon Joyce, Rebecca A Gillespie, John R Gallagher, Sarah F Andrews, Hadi M Yassine, Adam K Wheatley, Brian E Fisher, David R Ambrozak, Adrian Creanga, Kwanyee Leung, Eun Sung Yang, Seyhan Boyoglu-Barnum, Ivelin S Georgiev, Yaroslav Tsybovsky, Madhu S Prabhakaran, Hanne Andersen, Wing-Pui Kong, Ulrich Baxa, Kathryn L Zephir, Julie E Ledgerwood, Richard A Koup, Peter D Kwong, Audray K Harris, Adrian B McDermott, John R Mascola, Barney S Graham

Abstract

The present vaccine against influenza virus has the inevitable risk of antigenic discordance between the vaccine and the circulating strains, which diminishes vaccine efficacy. This necessitates new approaches that provide broader protection against influenza. Here we designed a vaccine using the hypervariable receptor-binding domain (RBD) of viral hemagglutinin displayed on a nanoparticle (np) able to elicit antibody responses that neutralize H1N1 influenza viruses spanning over 90 years. Co-display of RBDs from multiple strains across time, so that the adjacent RBDs are heterotypic, provides an avidity advantage to cross-reactive B cells. Immunization with the mosaic RBD-np elicited broader antibody responses than those induced by an admixture of nanoparticles encompassing the same set of RBDs as separate homotypic arrays. Furthermore, we identified a broadly neutralizing monoclonal antibody in a mouse immunized with mosaic RBD-np. The mosaic antigen array signifies a unique approach that subverts monotypic immunodominance and allows otherwise subdominant cross-reactive B cell responses to emerge.

Figures

Fig. 1.. Design and characterization of a…
Fig. 1.. Design and characterization of a mosaic array of heterotypic antigens on self-assembling nps.
(a) Design of HA RBD-np. Alteration in the residue 98 (Y98F) was made to abrogate sialic acid-binding property of HA. SP, signal peptide; T/C, transmembrane/cytoplasmic domains. (b) Negative-stain EM images of self-assembled HA RBD-nps. RBD-np were made using either single building blocks (left and middle) or two different building blocks (right). Shown are representative images from one experiment. (c) Antigenic characterization of RBD-np by immunoprecipitation (IP). The mAbs 3u-u (anti-NC99), 2D1 (anti-CA09) and C179 (anti-HA stem) were used to pull-down NC99, CA09 RBDs, and HA stem (control), respectively. Similar results were obtained from two independent experiments. (d) Schematic model of ferritin-based np. Twenty-four spatially dispersed antigens (colored individually) are displayed on the surface. Positions 2–6 are localized within a 100 Å distance from position 1. (e) Ferritin snub cube net with positions numbered similarly to panel d. Connected lines indicate adjacent positions located within 50–100 Å. (f) Twenty-four positions are colored according with the chromatic number (three) to avoid the same color from being located within 100 Å radius of each other. (g) Simulated likelihood of homologous antigen pairs made within 100 Å radius on a single particle by using 2, 4, 6 or 8 different building blocks (valence).
Fig. 2.. Immune induction by HA RBD-nps…
Fig. 2.. Immune induction by HA RBD-nps displaying homogeneous- and mosaic antigen arrays.
(a) Antibody responses to homologous NC99 virus. Serum HAI and pseudotype neutralization (PN) IC50 titers are measured after 2 immunizations of indicated valences of either admixed or mosaic RBD-nps with Sigma adjuvant system. For HAI, cumulative data of 3 independent experiments (n = 15) except for 8-valent admix group (2 independent experiments, n = 10) are shown. For PN, shown are representative data from one experiment (n = 5). Experiments are independently performed 3 times (2 times for 8-valent admix group) with similar results. Lines indicate means. Statistical analyses are done with one-way ANOVA with Tukey’s multiple comparisons post-hoc test. Non-statistical significance between groups is not shown for clarity. (b) Microneutralization (MN) IC50 titers against 5 different viruses in mice after priming with TIV and after boosting with mosaic RBD-np. Immune sera were collected at week 5 (prime) and 12 (boost). MN IC50 titers against each virus is plotted on five axes and connected by a line (n = 10). MN IC50 across 5 H1N1 viruses is shown as GMT ± geometric s.d. Statistical analyses are done with two-tailed paired t-test. Data are from one experiment. (c) Schematic representation of different immunization modalities. (d) Serum HAI titers to NC99 virus after 2 (NC99, admix and mosaic groups) or 4 (sequential) immunizations with adjuvant. Shown are representative data from one experiment (n = 10). Experiments are independently performed two times with similar results. Statistical analysis is done with one-way ANOVA with Tukey’s multiple comparison post-hoc test. (e) MN IC50 titers against 5 H1N1 viruses. MN IC50 titers are plotted as b. Shown are representative data from one experiment (n = 10). Experiments are independently performed two times with similar results. Statistical analysis is done with one-way ANOVA with Tukey’s multiple comparisons post-hoc test.
Fig. 3.. Induction of cross-reactive HA-specific B…
Fig. 3.. Induction of cross-reactive HA-specific B cells by RBD-nps.
(a) Gating strategy for identifying HA-specific B cells by flow cytometry. Anti-CD3, CD8, CD14, and F4/80 were combined and used to separate T cells, monocytes, and macrophages (MØ). A disparate pair of HAs (NC99 and CA09) was used to define cross-reactivity of HA-specific B cells. Frequencies of IgD− B cells specific to NC99 HA (b), CA09 (c), or cross-reactive to NC99 and CA09 (d) in PBMCs of mice immunized with different RBD-nps (n = 15, cumulative data of 3 independent experiments except for 8-valent admix group (n = 10, cumulative of 2 independent experiments). Statistical analyses are done with one-way ANOVA with Tukey’s multiple comparisons post-hoc test by using valence = 1 as a comparator. (e) Mutation rate in IGHV genes of individually sorted NC99 HA+ B cells isolated from immunized mice (n = 3, NC99, admix and mosaic; n = 2, sequential). Total productive IGHV genes obtained are 108, 98, 101 and 36 for NC99, admix, mosaic and sequential RBD-np groups, respectively. Statistical analysis is done with one-way ANOVA with Tukey’s multiple comparisons post-hoc test.
Fig. 4.. Biophysical and structural characterization of…
Fig. 4.. Biophysical and structural characterization of broadly-neutralizing antibody 441D6.
(a) Binding kinetics of 441D6 Fab to NY96 HA determined by biolayer interferometry (BLI). Measured sensorgram and calculated curve fit (1:1 binding model) are shown in black and red, respectively. Experiments were independently performed 2 times with similar results. (b) Summary of binding affinities of 441D6 Fab to a diverse set of 12 H1N1 HAs. Each HA–Fab interaction was plotted and color-coded based on year of virus identification. Binding kinetics details are found in Supplementary Fig. 4. (c) 2.0 Å crystal structure of unliganded 441D6 Fab. Somatic mutations of 441D6 Fab (right). Residues that underwent SHM are colored in blue. Amino acid sequence of CDRH1–3 and CDRL1–3 loops are shown with SHM residues in blue. (d) Cryo-EM structure of NY96 HA trimer in complex with 441D6 Fab. Side view along the longitudinal axis of an HA trimer (top) and top view looking down on the 3-fold axis of an HA trimer from the membrane distal end (bottom) are shown. Superimposition of NY96 HA (homology model, grey) and 441D6 Fab (orange-red) coordinates into the cryo-EM density map (right). White asterisks indicate sialic acid-binding pocket on each HA protomer. (e) Updated antigenic sites of H1N1 HA. Known antigenic sites Sa, Sb, Ca1, Ca2, and Cb are shown along with the site recognized by 441D6. (f) Surface conservation of 1,368 non-overlapping H1N1 HAs. Conservation scores were calculated by the ConSurf server (http://consurf.tau.ac.il) and colored on one NY96 HA protomer with dark blue equating to highest conservation. Predicted 441D6 epitope (colored) mapped on NY96 HA (g) and paratope of 441D6 (h). Each paratope residue is colored according to buried surface area (BSA) contribution. (i) Amino acid sequence of HA1 subunit of NY96 HA. 441D6 epitope residues are indicated by conservation score and BSA.
Fig. 5.. Breadth, potency, and potential mechanism…
Fig. 5.. Breadth, potency, and potential mechanism of neutralization of 441D6.
(a) Neutralization profile of bnAbs determined by a panel of 17 H1N1 pseudoviruses. Potency was displayed as a heatmap along with associated HA phylogenetic tree (maximum-likelihood method with full-length HA sequences). Antibodies 5J8 and CH65 (pan-H1N1 bnAbs targeting RBS) and C05 (cross-subtypic bnAb targeting RBS) were used as controls. Experiments are independently performed two times with similar results. (b) Neutralization breadth-potency plot generated from data displayed in a. Breadth denotes the neutralization coverage of a panel of 17 H1N1 strains representing > 90 years of antigenic evolution. MN IC50 (c) and HAI (d) of 441D6 against 6 different H1N1 viruses. Experiments are independently performed two times with similar results. (e) Hemolysis inhibitory activity of 441D6. Hemolysis inhibition assay was performed by using PR34 virus. The hemolysis is calculated with a formula: hemolysis (%) = {[Absexperimental - AbsRBC-only] / [Absno antibody - AbsRBC-only]} × 100. Experiments are independently performed two times. (f) MN activity of 441D6 in its IgG and Fab forms. MN IC50 concentrations of CH65, 441D6, and CR6261 were determined by MN assays with 2 H1N1 viruses. Experiments are independently performed two times with similar result. (g) Proposed model for neutralization by 441D6, CH65, and CR6261.
Fig. 6.. Neutralization activity in immune sera…
Fig. 6.. Neutralization activity in immune sera elicited by mosaic RBD-np.
(a) Serum HAI titers against a panel of 14 H1N1 viruses (> 30 years of coverage). HAI titers of immune sera elicited by mosaic RBD-np (8-valent) are plotted against the year of virus isolation (top) or plotted individually with breadth (bottom). (b) Serum PN IC50 titers against a panel of 13 H1N1 pseudoviruses (~90 years of coverage). Data are similarly represented as panel c. Shown are representative data from one experiment (n = 5). Experiments are independently performed two times with similar results.
Fig. 7.. Isolation and characterization of 441D6-like…
Fig. 7.. Isolation and characterization of 441D6-like antibodies from human PBMCs.
(a) Antibody cross-competition profile. Antibody binding to NC99 HA (left) and CA09 HA (right) was measured by BLI in the presence or absence of competing (1º) antibody. Antibody competition was calculated by a formula: competition (%) = 100 - {[Bmaxexperimental / Bmaxnon-competed] × 100}. Experiments are independently performed two times with similar results. (b) HA staining of human B cells. The sample was collected with informed consent of volunteer, and approval was obtained under protocol number VRC 310 (Clinicaltrials.gov NCT01086657). CD19+IgG+ B cells were probed with NC99 HA with 2 different fluorochromes (left) or probed with NC99 HA PE and NC99 HA–441D6 Fab complex APC (middle). CD19+IgG+ B cells stained with NC99 HA but not stained with HA–Fab complex (middle, green gate) were collected by single-cell sorting. Reactivity of NC99 HA+ HA–Fab complex− cells to CA09 HA BV785 and H3 A/Texas/50/2012 (TX12) HA AF488 was shown (right). Experiments are independently performed two times with similar results. (c) Neutralization breadth-potency plot of two representative 441D6-like human antibodies, 33–1F04 and 33–1G06. Neutralization breadth and potency were determined by PN assays using the same 17 virus panel as shown in Fig. 5. Experiments are independently performed two times with similar results.
Fig. 8.. Model of immunosubversion approach with…
Fig. 8.. Model of immunosubversion approach with mosaic antigen array.
(a) B cell activation by homotypic- or heterotypic antigen arrays. B cells possessing BCR specific to ‘gray’ antigen or cross-reactive to multiple antigenic variants are colored in gray or orange, respectively. Situations with particulate stimuli (e.g., virus, vaccine, etc.) made of homotypic (left) or heterotypic (right) antigens are shown. (b) Predicted immune outcome induced by homotypic- (top) and heterotypic (bottom) antigen arrays.

References

    1. Morens DM & Taubenberger JK Historical thoughts on influenza viral ecosystems, or behold a pale horse, dead dogs, failing fowl, and sick swine. Influenza Other Respir Viruses 4, 327–337 (2010).
    1. Bedford T et al. Integrating influenza antigenic dynamics with molecular evolution. Elife 3, e01914 (2014).
    1. Koel BF et al. Substitutions near the receptor binding site determine major antigenic change during influenza virus evolution. Science 342, 976–979 (2013).
    1. Smith DJ et al. Mapping the antigenic and genetic evolution of influenza virus. Science 305, 371–376 (2004).
    1. Webster RG, Laver WG, Air GM & Schild GC Molecular mechanisms of variation in influenza viruses. Nature 296, 115–121 (1982).
    1. Air GM Influenza virus antigenicity and broadly neutralizing epitopes. Curr Opin Virol 11, 113–121 (2015).
    1. Wrammert J et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med 208, 181–193 (2011).
    1. Joyce MG et al. Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses. Cell 166, 609–623 (2016).
    1. Whittle JR et al. Flow cytometry reveals that H5N1 vaccination elicits cross-reactive stem-directed antibodies from multiple Ig heavy-chain lineages. J Virol 88, 4047–4057 (2014).
    1. Li GM et al. Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells. Proc Natl Acad Sci U S A 109, 9047–9052 (2012).
    1. Schmidt AG et al. Viral receptor-binding site antibodies with diverse germline origins. Cell 161, 1026–1034 (2015).
    1. Andrews SF et al. Preferential induction of cross-group influenza A hemagglutinin stem-specific memory B cells after H7N9 immunization in humans. Sci Immunol 2 (2017).
    1. Ekiert DC et al. Cross-neutralization of influenza A viruses mediated by a single antibody loop. Nature 489, 526–532 (2012).
    1. Ekiert DC et al. Cross-neutralization of influenza A viruses mediated by a single antibody loop. Nature 489, 526–532 (2012).
    1. Whittle JR et al. Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin. Proc Natl Acad Sci U S A 108, 14216–14221 (2011).
    1. Lee PS et al. Receptor mimicry by antibody F045–092 facilitates universal binding to the H3 subtype of influenza virus. Nat Commun 5, 3614 (2014).
    1. Dreyfus C et al. Highly conserved protective epitopes on influenza B viruses. Science 337, 1343–1348 (2012).
    1. Ekiert DC et al. Antibody recognition of a highly conserved influenza virus epitope. Science 324, 246–251 (2009).
    1. Okuno Y, Isegawa Y, Sasao F & Ueda S A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. J Virol 67, 2552–2558 (1993).
    1. Corti D et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333, 850–856 (2011).
    1. Iba Y et al. Conserved neutralizing epitope at globular head of hemagglutinin in H3N2 influenza viruses. J Virol 88, 7130–7144 (2014).
    1. Krause JC et al. A broadly neutralizing human monoclonal antibody that recognizes a conserved, novel epitope on the globular head of the influenza H1N1 virus hemagglutinin. J Virol 85, 10905–10908 (2011).
    1. Xiong X et al. Structures of complexes formed by H5 influenza hemagglutinin with a potent broadly neutralizing human monoclonal antibody. Proc Natl Acad Sci U S A 112, 9430–9435 (2015).
    1. Impagliazzo A et al. A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen. Science 349, 1301–1306 (2015).
    1. Yassine HM et al. Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. Nat Med 21, 1065–1070 (2015).
    1. Mallajosyula VV et al. Influenza hemagglutinin stem-fragment immunogen elicits broadly neutralizing antibodies and confers heterologous protection. Proc Natl Acad Sci U S A 111, E2514–2523 (2014).
    1. Krammer F, Pica N, Hai R, Margine I & Palese P Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies. J Virol 87, 6542–6550 (2013).
    1. Victora GD & Nussenzweig MC Germinal centers. Annu Rev Immunol 30, 429–457 (2012).
    1. Doria-Rose NA & Joyce MG Strategies to guide the antibody affinity maturation process. Curr Opin Virol 11, 137–147 (2015).
    1. Lanzavecchia A, Fruhwirth A, Perez L & Corti D Antibody-guided vaccine design: identification of protective epitopes. Curr Opin Immunol 41, 62–67 (2016).
    1. Kanekiyo M et al. Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site. Cell 162, 1090–1100 (2015).
    1. Kanekiyo M et al. Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature 499, 102–106 (2013).
    1. Zimmer SM & Burke DS Historical perspective--Emergence of influenza A (H1N1) viruses. N Engl J Med 361, 279–285 (2009).
    1. Xu R et al. Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus. Science 328, 357–360 (2010).
    1. Dintzis HM, Dintzis RZ & Vogelstein B Molecular determinants of immunogenicity: the immunon model of immune response. Proc Natl Acad Sci U S A 73, 3671–3675 (1976).
    1. Bachmann MF et al. The influence of antigen organization on B cell responsiveness. Science 262, 1448–1451 (1993).
    1. Tiller T, Busse CE & Wardemann H Cloning and expression of murine Ig genes from single B cells. J Immunol Methods 350, 183–193 (2009).
    1. Gerhard W, Yewdell J, Frankel ME & Webster R Antigenic structure of influenza virus haemagglutinin defined by hybridoma antibodies. Nature 290, 713–717 (1981).
    1. Caton AJ, Brownlee GG, Yewdell JW & Gerhard W The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype). Cell 31, 417–427 (1982).
    1. Hong M et al. Antibody recognition of the pandemic H1N1 Influenza virus hemagglutinin receptor binding site. J Virol 87, 12471–12480 (2013).
    1. Yewdell JW, Gerhard W & Bachi T Monoclonal anti-hemagglutinin antibodies detect irreversible antigenic alterations that coincide with the acid activation of influenza virus A/PR/834-mediated hemolysis. J Virol 48, 239–248 (1983).
    1. Raymond DD et al. Conserved epitope on influenza-virus hemagglutinin head defined by a vaccine-induced antibody. Proc Natl Acad Sci U S A 115, 168–173 (2018).
    1. Neu KE, Henry Dunand CJ & Wilson PC Heads, stalks and everything else: how can antibodies eradicate influenza as a human disease? Curr Opin Immunol 42, 48–55 (2016).
    1. Lambert LC & Fauci AS Influenza vaccines for the future. N Engl J Med 363, 2036–2044 (2010).
    1. Hai R et al. Influenza viruses expressing chimeric hemagglutinins: globular head and stalk domains derived from different subtypes. J Virol 86, 5774–5781 (2012).
    1. Carter DM et al. Elicitation of protective antibodies against a broad panel of H1N1 viruses in ferrets pre-immune to historical H1N1 influenza viruses. J Virol (2017).
    1. Carter DM et al. Design and Characterization of a Computationally Optimized Broadly Reactive Hemagglutinin Vaccine for H1N1 Influenza Viruses. J Virol 90, 4720–4734 (2016).
    1. Belongia EA et al. Repeated annual influenza vaccination and vaccine effectiveness: review of evidence. Expert Rev Vaccines 16, 1–14 (2017).
    1. Chai N et al. A broadly protective therapeutic antibody against influenza B virus with two mechanisms of action. Nat Commun 8, 14234 (2017).
    1. Shen C et al. A multimechanistic antibody targeting the receptor binding site potently cross-protects against influenza B viruses. Sci Transl Med 9 (2017).
    1. Ngwuta JO et al. Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera. Sci Transl Med 7, 309ra162 (2015).
    1. Ledgerwood JE et al. Prime-boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect. J Infect Dis 208, 418–422 (2013).
    1. Wei CJ et al. Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 329, 1060–1064 (2010).
    1. Wheatley AK et al. H5N1 Vaccine-Elicited Memory B Cells Are Genetically Constrained by the IGHV Locus in the Recognition of a Neutralizing Epitope in the Hemagglutinin Stem. J Immunol 195, 602–610 (2015).
    1. Brochet X, Lefranc MP & Giudicelli V IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis. Nucleic Acids Res 36, W503–508 (2008).
    1. Kong WP et al. Protective immunity to lethal challenge of the 1918 pandemic influenza virus by vaccination. Proc Natl Acad Sci U S A 103, 15987–15991 (2006).
    1. Yang ZY et al. Immunization by avian H5 influenza hemagglutinin mutants with altered receptor binding specificity. Science 317, 825–828 (2007).
    1. Mastronarde DN Automated electron microscope tomography using robust prediction of specimen movements. Journal of structural biology 152, 36–51 (2005).
    1. Schindelin J et al. Fiji: an open-source platform for biological-image analysis. Nature methods 9, 676–682 (2012).
    1. Yu X et al. Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors. Nature 455, 532–536 (2008).
    1. Misasi J et al. Structural and molecular basis for Ebola virus neutralization by protective human antibodies. Science 351, 1343–1346 (2016).
    1. Otwinowski Z & Minor W Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol 276, 307–326 (1997).
    1. Emsley P, Lohkamp B, Scott WG & Cowtan K Features and development of Coot. Acta Crystallogr D Biol Crystallogr 66, 486–501 (2010).
    1. Adams PD et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr 66, 213–221 (2010).
    1. Pettersen EF et al. UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem 25, 1605–1612 (2004).
    1. Li X et al. Electron counting and beam-induced motion correction enable near-atomic-resolution single-particle cryo-EM. Nat Methods 10, 584–590 (2013).
    1. Rohou A & Grigorieff N CTFFIND4: Fast and accurate defocus estimation from electron micrographs. J Struct Biol 192, 216–221 (2015).
    1. Scheres SH RELION: implementation of a Bayesian approach to cryo-EM structure determination. J Struct Biol 180, 519–530 (2012).
    1. Scheres SH Semi-automated selection of cryo-EM particles in RELION-1.3. J Struct Biol 189, 114–122 (2015).
    1. Tang G et al. EMAN2: an extensible image processing suite for electron microscopy. J Struct Biol 157, 38–46 (2007).
    1. Kimanius D, Forsberg BO, Scheres SH & Lindahl E Accelerated cryo-EM structure determination with parallelisation using GPUs in RELION-2. Elife 5 (2016).
    1. Zheng SQ et al. MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. Nat Methods 14, 331–332 (2017).

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren